The pilot study conducted by the Hospital for Special Surgery aimed to evaluate the safety and efficacy of rTMS in treating depression symptoms among ALS patients and other neurodegenerative disorders. The trial was terminated due to not meeting target enrollment, indicating potential challenges in patient recruitment for this niche indication. The market for ALS therapies is competitive, with a growing focus on addressing comorbidities such as depression. Companies developing non-invasive brain stimulation technologies may find opportunities in this area, particularly if they can demonstrate robust efficacy and safety profiles. The study's termination may raise concerns regarding the viability of rTMS as a treatment option in this patient population, necessitating further investigation into patient engagement and recruitment strategies.